福美坦治疗晚期乳腺癌
Treatment of advanced breast cancer with formestane.
作者信息
Murray R, Pitt P
机构信息
Peter MacCallum Cancer Institute, Melbourne, Australia.
出版信息
Ann Oncol. 1994;5 Suppl 7:S11-3.
A total of 147 postmenopausal or postoophorectomy patients with advanced breast cancer resistant to standard endocrine therapies were treated with the potent aromatase inhibitor formestane (Lentaron). Among those available for assessment (n = 143), 32 (22%) had a partial response, while another 28 (20%) had stabilization of previously progressive disease. Patients responded to formestane irrespective of whether they had responded to, or failed to respond to, tamoxifen, medroxyprogesterone acetate, aminoglutethimide and trilostane. Toxicity was minimal. We conclude that formestane is an effective and non-toxic therapeutic agent for the treatment of women with advanced breast cancer.
共有147例对标准内分泌治疗耐药的绝经后或卵巢切除术后晚期乳腺癌患者接受了强效芳香化酶抑制剂福美司坦（兰特隆）治疗。在可进行评估的患者中（n = 143），32例（22%）出现部分缓解，另有28例（20%）之前进展的病情得到稳定。无论患者对他莫昔芬、醋酸甲羟孕酮、氨鲁米特和曲洛司坦是否有反应，他们对福美司坦均有反应。毒性极小。我们得出结论，福美司坦是治疗晚期乳腺癌女性患者的一种有效且无毒的治疗药物。
Zotero 插件